GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagenic Therapeutics Inc (NAS:PTIX) » Definitions » Shiller PE Ratio

Protagenic Therapeutics (Protagenic Therapeutics) Shiller PE Ratio : (As of May. 15, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Protagenic Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Protagenic Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Protagenic Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagenic Therapeutics Shiller PE Ratio Chart

Protagenic Therapeutics Annual Data
Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Protagenic Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Protagenic Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Protagenic Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagenic Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's Shiller PE Ratio falls into.



Protagenic Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Protagenic Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Protagenic Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.38/129.4194*129.4194
=-0.380

Current CPI (Dec. 2023) = 129.4194.

Protagenic Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -56.923 99.695 -73.895
201406 -14.769 100.560 -19.008
201409 -17.231 100.428 -22.205
201412 -20.462 99.070 -26.730
201503 -18.308 99.621 -23.784
201506 -17.231 100.684 -22.149
201509 -20.154 100.392 -25.981
201512 -24.308 99.792 -31.525
201603 -211.320 100.470 -272.209
201606 -0.320 101.688 -0.407
201609 -0.240 101.861 -0.305
201612 -0.217 101.863 -0.276
201703 -0.240 102.862 -0.302
201706 -0.160 103.349 -0.200
201709 -0.160 104.136 -0.199
201712 -0.280 104.011 -0.348
201803 -0.240 105.290 -0.295
201806 -0.280 106.317 -0.341
201809 -0.200 106.507 -0.243
201812 -0.320 105.998 -0.391
201903 -0.240 107.251 -0.290
201906 -0.120 108.070 -0.144
201909 -0.040 108.329 -0.048
201912 -0.280 108.420 -0.334
202003 -0.200 108.902 -0.238
202006 -0.240 108.767 -0.286
202009 -0.400 109.815 -0.471
202012 -0.200 109.897 -0.236
202103 -0.440 111.754 -0.510
202106 -0.440 114.631 -0.497
202109 -0.200 115.734 -0.224
202112 -0.200 117.630 -0.220
202203 -0.320 121.301 -0.341
202206 -0.150 125.017 -0.155
202209 -0.210 125.227 -0.217
202212 -0.140 125.222 -0.145
202303 -0.170 127.348 -0.173
202306 -0.280 128.729 -0.282
202309 -0.320 129.860 -0.319
202312 -0.380 129.419 -0.380

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Protagenic Therapeutics  (NAS:PTIX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Protagenic Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Protagenic Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Protagenic Therapeutics (Protagenic Therapeutics) Business Description

Traded in Other Exchanges
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Executives
Alexander K. Arrow officer: Chief Financial Officer PO BOX 3094, REDWOOD CITY CA 94064
Jennifer Buell director 3 FORBES ROAD, LEXINGTON MA 02421
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Robert Benjamin Stein director C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Khalil Barrage director 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Gregory Ekizian director 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Robert Ziroyan officer: COO / Interim President 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Garo H Armen director, 10 percent owner, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Edward J Gildea director, officer: Chief Executive Officer C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
David J Horin officer: Chief Financial Officer 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Nathan Yu-gai Fong officer: Chief Financial Officer THE ORCHARD ENTERPRISES, INC., 23 E. 4TH ST., 3RD FL., NEW YORK NY 10003
Sharon Siegel officer: Chief Marketing Officer C/O ATRINSIC, INC., 469 SEVENTH AVENUE, 10TH FLOOR, NEW YORK NY 10018
Raymond Musci director, officer: Exec VP, Corporate Development C/O BRILLIANT DIGITAL ENTERTAINMENT INC, 6355 TOPANGA CANYON BOULEVARD SUITE 520, WOODLAND HILLS CA 91367

Protagenic Therapeutics (Protagenic Therapeutics) Headlines

From GuruFocus

Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split

By ACCESSWIRE ACCESSWIRE 03-22-2023